Portal de Periódicos da CAPES

Ophthalmologic Aspects of Chloroquine and Hydroxychloroquine Therapy

1983; Wiley; Volume: 22; Issue: 5 Linguagem: Inglês

10.1111/j.1365-4362.1983.tb02137.x

1365-4632

Jane Z. Portnov, Jeffrey P. Callen,

Chronic Lymphocytic Leukemia Research

International Journal of DermatologyVolume 22, Issue 5 p. 273-278 Ophthalmologic Aspects of Chloroquine and Hydroxychloroquine Therapy Jane Z. Portnov M.D., Jane Z. Portnov M.D. From the Departments of Ophthalmology and Medicine (Dermatology), University of Louisville School of Medicine Louisville, KentuckySearch for more papers by this authorJeffrey P. Callen M.D., Corresponding Author Jeffrey P. Callen M.D. From the Departments of Ophthalmology and Medicine (Dermatology), University of Louisville School of Medicine Louisville, KentuckyReprint requests to: Jeffrey P, Callen, M.D., 554 Medical Towers South, Louisville, KY 40202.Search for more papers by this author Jane Z. Portnov M.D., Jane Z. Portnov M.D. From the Departments of Ophthalmology and Medicine (Dermatology), University of Louisville School of Medicine Louisville, KentuckySearch for more papers by this authorJeffrey P. Callen M.D., Corresponding Author Jeffrey P. Callen M.D. From the Departments of Ophthalmology and Medicine (Dermatology), University of Louisville School of Medicine Louisville, KentuckyReprint requests to: Jeffrey P, Callen, M.D., 554 Medical Towers South, Louisville, KY 40202.Search for more papers by this author First published: June 1983 https://doi.org/10.1111/j.1365-4362.1983.tb02137.xCitations: 10AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Tanenbaum L, Tuffanelli DL: Antimalarial agents. Arch Dermatol 116: 587, 1980. 2 Sams WM Jr: Chloroquine: Its therapeuric use in photosensitive eruptions. Int J Dermatol 15: 99, 1976. 3 Logan WS: Antimalarials Prog Dermatol 14: 1, 1980. 4 Bunch TW, O'Duffy JD: Disease-modifying drugs for progressive rheumatoid arthritis. Proc Mayo Clin 55: 161, 1980. 5 Tuffanelli DL: Antimalarials. Personal communication. June 29, 1981. 6 Hobbs HE, Calnan CD: The ocular complications of chloroquine therapy. Lancet i: 1207, 1958. 7 Hobbs HE, Sorsby A, Freedman A: Retinopathy following chloroquine therapy. Lancet ii: 478, 1959. 8 Berliner RW, Earle DP, Taggart JV, et al: Studies on the Chemotherapy of the human malarials, VI, The physiological disposition, antimalarial activity, and toxicity of several derivatives of 4-aminoquinoline. J Clin Invest 27: 98, 1948. 9 Bernstein H, Zvaifler N, Rubin M, et al: The ocular deposition of chloroquine. Invest Ophthal 2: 384, 1963. 10 Zvaifler NJ, Bernstein H, Rubin M: Chloroquine deposition in ocular tissues. Arth Rheum 5: 667, 1962. 11 Shaffer B, Cahn MM, Levy EJ: Absorption of antimalarial drugs in human skin: Spectrosropic and chemical analysis in epidermis and corium. J Invest Dermatol 30: 341, 1958. 12 Potts AM: The reaction of uveal pigment in vitro with polycylic compounds. Invest Ophthal 3: 405, 1964. 13 Shearer RV, Dubois EL: Ocular changes induced by long-term hydroxychloroquine (plaquenil®) therapy. Am J Ophthal 64: 245, 1967. 14 Rowell R: Treatment of discoid lupus erythematosus. Trans St John Hosp Dermatol Soc 39: 48, 1957. 15 Tuffanelli DL, Abraham R, Dubois E: Pigmentation from antimalarial therapy. Arch Dermatol 88: 419, 1963. 16 Potts AM: Further studies concerning the accumulation of polycyclic compounds on uveal melanin. Invest Ophthal 3: 399, 1964. 17 Rubin M, Bernstein HN, Zvaifler NJ: Studies on the pharmacology of Chloroquine: Recommendations for the treatment of retinopathy. Arch Ophthal 70: 474, 1963. 18 Cohen S, Yielding K: Stabilization of the structure of native DNA by chloroquine and observation on the nature of the chloroquine-DNA complex. (Abstract) 10th session. Am Rheum Assn Dec 6, 1963. 19 Sams WM Jr, Carroll NV: The “spectral shift” phenomenon of chloroquine. Arch Dermatol 93: 123, 1966. 20 Bowness J, Morton R: Distribution of copper and zinc in the eyes of fresh water fishes and frogs. Occurrence of metals in melanin fractions from eve tissues. Biochem J 53: 530, 1952. 21 Goha-sun LM, Potts AM: In vitro inhibition of protein synthesis in the retinal pigment epithelium by chloroquine. Invest Ophthal 13: 107, 1974. 22 Lie SO, Schofield B: Inactivation of lysosomal function in normal cultured human fibroblasts by chloroquine. Biochem Pharmacol 22: 3109, 1973. 23 Hobbs H, Eadie S, Somerville F: Ocular lesions after treatment with chloroquine. Br J Ophthalmol 45: 284, 1961. 24 Henkind P, Rothfield N: Ocular abnormalities in patients treated with synthetic antimalarial drugs. N Engl J Med 269: 433, 1963. 25 Sandvig K: Chloroquine (Resochin) effects on the cornea. Acta Ophthalmol 44: 355, 1966. 26 Scherbel A, Mackenzie A, Nousek JE, et al: Ocular lesions in rheumatoid arthritis and related disorders with particular reference to retinopathy: A study of 741 patients treated with and without chloroquine drugs. N Engl J Med 273: 360, 1965. 27 Bernstein HN: Chloroquine ocular toxicity. Surv Ophthalmol 12: 415, 1967. 28 Rynes RI, Krohel G, Falbo A, et al: Ophthalmic safety of long-term hydroxychloroquine treatment. Arch Rheum 22: 832, 1979. 29 Carr RE, Gouras P, Gunkel RD: Chloroquine retinopathy: Early detection by retinal threshold test. Arch Ophthalmol 75: 171, 1966. 30 Bernstein HN, Ginsberg J: The pathology of Chloroquine retinopathy. Arch Ophthalmol 71: 238, 1964. 31 Wetterholm DH, Winter FC: Histopathology of chloroquine retinal toxicity. Arch Ophthalmol 71: 82, 1964. 32 Abraham R, Hendy RJ: Irreversible lysosomal damage induced by chloroquine in the retinae of pigmented and albino rats. Exper Molec Pathol 12: 185, 1970. 33 Nylander U: Ocular damage in chloroquine therapy. Acta Ophthalmol 45 (suppl 92): 5, 1967. 34 Voipio H: Incidence of chloroquine retinopathy. Acta Ophthalmol 44: 349, 1966. 35 Young P, Isbey E, Briggs H, Brosnan D: Chloroquine retinopathy—A preliminary report of a five year study. Arthr Rheum 9: 552, 1966. 36 Laaksonen A, Koskiahde V, Juva K: Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. Scand J Rheumatology 3: 103, 1974. 37 Mackenzie AH: Ocular safety of the huge cumulative antimalarial dosage. Arth Rheum (Abstract 74) 24 (Suppl) 570, 1981. 38 Tobin DR, Krohel GB, Rynes RI: Hydroxychloroquine: Seven-year experience. Arch Ophthalmol 100: 81, 1982. 39 Okun E, Gouras P, Bernstein H, et al: Chloroquine retinopathy. Arch Opthalmol 69: 59, 1963. 40 Henkind P, Carr RE, Siegel IM: Early chloroquine retinopathy: Clinical and functional findings. Arch Ophthalmol 71: 157, 1964. 41 Percival SPB, Meanock I: Chloroquine: Ophthalmological safety, and clinical assessment in rheumatoid arthritis. Br Med J 3: 579, 1968. 42 Percival SPB, Behrman J: Ophthalmological safety of chloroquine. Br J Ophthalmol 53: 101, 1969. 43 Carr RE, Henkind P, Rothfield N, et al: Ocular toxicity of antimalarial drugs: Long-term follow-up. Am J Ophthalmol 66: 738, 1968. 44 Arden GB, Fojas MR: Electrophysiological abnormalities in pigmentary degenerations of the retina. Arch Opthalmol 68: 369, 1962. 45 Arden GB, Barrada A: Analysis of the electro-oculogram of a series of normal subjects. Br J Ophthalmol 46: 468, 1962. 46 Kolb H: Electro-oculogram findings in patients treated with antimalarial drugs. Br J Ophthalmol 49: 573, 1965. 47 van Lith GHM, Mak GTM, Wijnands H: Clinical imoportance of the electro-oculogram with special reference to the chloroquine retinopathy. Bibl Ophthalmol 85: 2, 1976. 48 Graniewski-Wijnands HS, van Lith GHM, Vijfvinkel-Bruinenga S: Ophthalmological examination of patients taking chloroquine. Doc Ophthalmol 48: 231, 1979. 49 Schmidt B, Muller-Limmroth W: Electroretinographic examinations following the application of chloroquine. Acta Ophthalmol 70 (Suppl): 245, 1962. 50 Krill AE, Potts AM, Johanson CE: Chloroquine retinopathy: Investigation between dark adaptation and electroretinographic findings in advanced stages. Am J Ophthalmol 71: 530, 1971. 51 Brinkley JR, Dubois EL, Ryan SJ: Long-term course of chloroquine retinopathy after cessation of medication. Am J Ophthalmol 88: 1, 1979. 52 Burns RP: Delayed onset of chloroquine retinopathy. N Engl J Med 275: 693, 1966. 53 Martin LJ, Bergen RL, Dobrow HR: Delayed onset chloroquine retinopathy: Case report. Ann Ophthalmol 10: 723, 1978. Citing Literature Volume22, Issue5June 1983Pages 273-278 ReferencesRelatedInformation